ArticleThe Journal of dermatology2023
Prevalence of alopecia areata in Japan: Estimates from a nationally representative sample.
Article in The Journal of dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial.The Journal of dermatology · 2025Trial
- Alopecia Areata Prevalence in Australia: Insights From a Nationally Representative Cross-Sectional Survey Study.The Australasian journal of dermatology · 2026Article
- The Association Between Alopecia Areata and Iron Deficiency Anemia: A Large-Scale Population-Based Case-Control Study.Journal of personalized medicine · 2026Article
- Real-World Outcomes of Baricitinib and Ritlecitinib in Refractory Alopecia Areata: Response Predictors and Relapse After Discontinuation or Dose Reduction.The Journal of dermatology · 2026Article
- Cost-Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan.The Journal of dermatology · 2026Article
- Dermatologists' Perspectives and Real-World Assessment of Alopecia Areata Severity in Adults in Taiwan: A Cross-sectional Survey.Dermatology and therapy · 2026Article
- Perceived Stigma and Mental Health Disorders Among Adults With Alopecia Areata Living in Japan.The Journal of dermatology · 2025Article
- Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study.Frontiers in medicine · 2025Article
- Taste disorders and alopecia in myasthenia gravis.BMC neurology · 2024Article
- Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale.Breast cancer (Tokyo, Japan) · 2024Article
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases.Journal of clinical medicine · 2023Review
- Prevalence of alopecia areata in Japan: Estimates from a nationally representative sample.The Journal of dermatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
Data on the prevalence of alopecia areata (AA) in Japan is limited and the epidemiology of the disease there is not well understood; therefore, it is critical to examine the prevalence and severity of AA in Japan to inform the need for future treatments and research. A cross-sectional, web-based survey was conducted in Japan from January through March 2021. A total of 45 006 participants were identified through general population survey panels and asked about their experience with AA and hair loss. The Alopecia Assessment Tool and the Scalp Hair Assessment PRO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.